These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37342874)

  • 1. OPTIMAL PLASMA CONCENTRATION OF THROMBOMODULIN ALFA TO TREAT SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION.
    Imaura M; Katagiri F; Nagase S; Hatoyama-Tanaka S; Takahashi H; Takayanagi R; Kanno H; Yamada Y
    Shock; 2023 Aug; 60(2):221-226. PubMed ID: 37342874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.
    Imaura M; Tsumori M; Nagase S; Omura K; Takahashi H; Hatoyama-Tanaka S; Katagiri F; Takayanagi R; Kanno H; Yamada Y
    Shock; 2020 Jul; 54(1):50-55. PubMed ID: 31764622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation.
    Murao A; Kato T; Yamane T; Honda G; Eguchi Y
    Clin Appl Thromb Hemost; 2022; 28():10760296221077096. PubMed ID: 35166576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
    Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
    Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
    Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anticoagulant treatment for sepsis induced disseminated intravascular coagulation; network meta-analysis.
    Yatabe T; Inoue S; Sakamoto S; Sumi Y; Nishida O; Hayashida K; Hara Y; Fukuda T; Matsushima A; Matsuda A; Yasuda H; Yamashita K; Egi M
    Thromb Res; 2018 Nov; 171():136-142. PubMed ID: 30312798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
    Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
    Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
    Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
    Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
    Aikawa N; Shimazaki S; Yamamoto Y; Saito H; Maruyama I; Ohno R; Hirayama A; Aoki Y; Aoki N
    Shock; 2011 Apr; 35(4):349-54. PubMed ID: 21068698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
    Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
    Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis.
    Okuda A; Ogura T; Imanishi M; Miyano A; Nishioka N; Higuchi K
    Gut Liver; 2018 Jul; 12(4):471-477. PubMed ID: 29699063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
    Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
    Papageorgiou C; Jourdi G; Adjambri E; Walborn A; Patel P; Fareed J; Elalamy I; Hoppensteadt D; Gerotziafas GT
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):8S-28S. PubMed ID: 30296833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
    Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
    Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
    Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis.
    Lin SM; Wang YM; Lin HC; Lee KY; Huang CD; Liu CY; Wang CH; Kuo HP
    Crit Care Med; 2008 Mar; 36(3):683-9. PubMed ID: 18431261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.